Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Overview
Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Companies Involved in Therapeutics Development
Crescendo Biologics Ltd
Hookipa Pharma Inc
Inovio Pharmaceuticals Inc
Kleo Pharmaceuticals Inc
Orpheris Inc
Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Drug Profiles
CB-307 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-5150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-5151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-5401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-0832 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OP-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Prostate Specific Membrane Antigen for Rel Cell Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target PSMA and TARP for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target PSMA, STEAP1 and PAP for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Dormant Products
Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Discontinued Products
Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Product Development Milestones
Featured News & Press Releases
Nov 05, 2019: Inovio demonstrates 80% 6-month progression-free survival in phase 2 Glioblastoma Multiforme (GBM) study with INO-5401 in combition with PD-1 inhibitor Libtayo (cemiplimab)
Jun 24, 2019: Crescendo Biologics to present preclinical data on its lead Humabody candidate, CB307, at the Cell Engager Therapeutics Summit 2019
Apr 03, 2019: Inovio closes enrolment in Phase I/II glioblastoma trial
Oct 22, 2018: Inovio Presents Progression Free Survival & PSA Doubling Time Improvements in Prostate Cancer Patients Treated with INO-5150
Oct 18, 2018: Crescendo Biologics appoints SVP CMC, Dr Richard Williams, and new CDMO partner, as it advances towards the clinic
Aug 20, 2018: Inovio doses first patient in Phase l/lla of INO-5401 and atezolizumab
Jun 21, 2018: Inovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combition with Regeneron’s PD-1 Inhibitor
May 17, 2018: Inovio Pharmaceuticals Demonstrates PSA Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for Prostate Cancer
Nov 27, 2017: Inovio Pharmaceuticals SynCon TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor Model
Nov 01, 2017: Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combition with Regenerons PD-1 Inhibitor
Sep 11, 2017: Inovios Cancer Immunotherapy (INO-5150) Slowed PSA Rise and Significantly Increased PSA Doubling Times In Patients with Recurrent Prostate Cancer
Jul 27, 2015: Inovio Pharmaceuticals Initiates Clinical Trial of INO-5150 D Immunotherapy for Prostate Cancer
Feb 02, 2011: Inovio’s Dual-Antigen SynCon D Vaccine For Prostate Cancer Induces Robust Responses In Preclinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Crescendo Biologics Ltd, H2 2019
Pipeline by Hookipa Pharma Inc, H2 2019
Pipeline by Inovio Pharmaceuticals Inc, H2 2019
Pipeline by Kleo Pharmaceuticals Inc, H2 2019
Pipeline by Orpheris Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019